# EDGAR Filing Document

**Accession Number:** 0000353278
**File Stem:** 0001171843-23-000647
**Filing Date:** 2023-2
**Character Count:** 84528
**Document Hash:** c45f371470f94d8a1b56d5662b4207c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000647.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0001171843-23-000647

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230202

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVO NORDISK A S
- **CENTRAL INDEX KEY:** 0000353278
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-82318
- **FILM NUMBER:** 23583597

**BUSINESS ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000
- **BUSINESS PHONE:** 4544448888

**MAIL ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO NORDISK A/S
- **DATE OF NAME CHANGE:** 19900807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO INDUSTRI A S /DENMARK/
- **DATE OF NAME CHANGE:** 19890811

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

***________________***

**FORM 6-K**

***________________***

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

February 2, 2023

***________________***

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé** 

**DK- 2880, Bagsvaerd** 

**Denmark**

(Address of principal executive offices)

***________________***

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X] Form 40-F [ ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [ ] No [X]

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

![](logo.jpg)

![](ca.jpg)

### Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 2 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Elisabeth Dahl Christensen |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 1,345 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 1,345 Shares<br> DKK 0.00 | <br> 1,345 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Liselotte Sofie Hyveled |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Mette Bøjer Jensen | Mette Bøjer Jensen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Member of the Board of Directors | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | |
|:---|:---|:---|
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Maha Kutay | Maha Kutay |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Closely related to Kasim Kutay, member of the Board of Directors | Closely related to Kasim Kutay, member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Purchase of shares | Purchase of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 964.25 | 434 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume | <br> 434 Shares | <br> 434 Shares |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

<u>· Price</u> <u>DKK 964.25</u> <br> <u>e)</u> <u>Date of the transaction</u> <u>2023-02-01</u> <br> <u>f)</u> <u>Place of the transaction</u> <u>NASDAQ COPENHAGEN A/S (XCSE)</u>

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Thomas Rantzau | Thomas Rantzau |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Member of the Board of Directors | Member of the Board of Directors |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO | President and CEO |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 86,083 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 86,083 Shares<br> DKK 0.00 | <br> 86,083 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO | President and CEO |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Position/status | President and CEO | President and CEO |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 944.76 | 3,396 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 3,396 Shares<br> DKK 944.76 | <br> 3,396 Shares<br> DKK 944.76 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | AQUIS EXCHANGE EUROPE (AQEU) | AQUIS EXCHANGE EUROPE (AQEU) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 942.91 | 13,847 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 13,847 Shares<br> DKK 942.91 | <br> 13,847 Shares<br> DKK 942.91 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | CBOE EUROPE (BEUP) | CBOE EUROPE (BEUP) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument, type of instrument, | Shares |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 939.70 | 77 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 77 Shares<br> DKK 939.70 | <br> 77 Shares<br> DKK 939.70 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | CBOE EUROPE - DXE DARK ORDER BOOK (NL) (CEUD) | CBOE EUROPE - DXE DARK ORDER BOOK (NL) (CEUD) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) | Price(s) |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| | | DKK 944.88 | 6,449 shares |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 6,449 Shares<br> DKK 944.88 | <br> 6,449 Shares<br> DKK 944.88 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | CBOE EUROPE - DXE ORDER BOOKS (NL) (CEUX) | CBOE EUROPE - DXE ORDER BOOKS (NL) (CEUX) |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO | President and CEO |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 944.03 | 3,503 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information |  |  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price</u> <u>3,503 Shares DKK 944.03</u> <br> <u>e)</u> <u>Date of the transaction</u> <u>2023-02-01</u> <br> <u>f)</u> <u>Place of the transaction</u> <u>SIGMA X EUROPE AUCTION BOOK (SGMV)</u>

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO | President and CEO |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 942.74 | 38 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 38 Shares<br> DKK 942.74 | <br> 38 Shares<br> DKK 942.74 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | TURQUOISE EUROPE (TQEX) | TURQUOISE EUROPE (TQEX) |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | Lars Fruergaard Jørgensen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | President and CEO | President and CEO |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 943.23 | 22,690 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 22,690 Shares<br> DKK 943.23 | <br> 22,690 Shares<br> DKK 943.23 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S (XCSE) | NASDAQ COPENHAGEN A/S (XCSE) |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Monique Carter |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 8,963 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 8,963 Shares<br> DKK 0.00 | <br> 8,963 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Monique Carter |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 26,984 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 26,984 Shares<br> DKK 0.00 | <br> 26,984 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument, type of instrument, | Shares |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares |
| c) | Price(s) and volume(s) |  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| | | Price(s) | Volume(s) |
| | | DKK 949.99 | 1,434 shares |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 1,434 Shares<br> DKK 949.99 | <br> 1,434 Shares<br> DKK 949.99 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | OUTSIDE A TRADING VENUE | OUTSIDE A TRADING VENUE |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | Ludovic Helfgott |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 24,286 shares |
| c) | Price(s) and volume(s) |  |  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

d) Aggregated information &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; · Aggregated volume &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; · Price 24,286 Shares DKK 0.00

e) Date of the transaction 2023-02-01

f) Place of the transaction Outside
 a trading venue

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | Ludovic Helfgott |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume | <br> 75 Shares | <br> 75 Shares |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

<u>· Price</u> <u>DKK 0.00</u> <br> <u>e)</u> <u>Date of the transaction</u> <u>2023-02-01</u> <br> <u>f)</u> <u>Place of the transaction</u> <u>Outside a trading venue</u>

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Ludovic Helfgott | Ludovic Helfgott |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 949.99 | 6,929 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 6,929 Shares<br> DKK 949.99 | <br> 6,929 Shares<br> DKK 949.99 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | OUTSIDE A TRADING VENUE | OUTSIDE A TRADING VENUE |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | Karsten Munk Knudsen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 24,286 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 24,286 Shares<br> DKK 0.00 | <br> 24,286 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | Karsten Munk Knudsen |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa |
| **2** | **Reason for the notification** | **Reason for the notification** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 26,984 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 26,984 Shares<br> DKK 0.00 | <br> 26,984 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Douglas Langa |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 949.99 | 13,914 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 13,914 Shares<br> DKK 949.99 | <br> 13,914 Shares<br> DKK 949.99 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | OUTSIDE A TRADING VENUE | OUTSIDE A TRADING VENUE |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| | | accordance with Long Term Incentive programme) | accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 10,978 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 10,978 Shares<br> DKK 0.00 | <br> 10,978 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Martin Holst Lange |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |
| a) | Identification code | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| | | Price(s) | Volume(s) |
| | | DKK 0.00 | 75 shares |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | Marcus Schindler |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 10,978 shares |
| c) | Price(s) and volume(s) |  |  |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

d) Aggregated information &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; · Aggregated volume &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; · Price 10,978 Shares DKK 0.00

e) Date of the transaction 2023-02-01

f) Place of the transaction Outside
 a trading venue

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | Marcus Schindler |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume | <br> 75 Shares | <br> 75 Shares |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

<u>· Price</u> <u>DKK 0.00</u> <br> <u>e)</u> <u>Date of the transaction</u> <u>2023-02-01</u> <br> <u>f)</u> <u>Place of the transaction</u> <u>Outside a trading venue</u>

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Marcus Schindler | Marcus Schindler |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Sale of shares | Sale of shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 944.96 | 5,000 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 5,000 Shares<br> DKK 944.96 | <br> 5,000 Shares<br> DKK 944.96 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | NASDAQ COPENHAGEN A/S (XCSE) | NASDAQ COPENHAGEN A/S (XCSE) |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | Camilla Sylvest |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 24,286 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 24,286 Shares<br> DKK 0.00 | <br> 24,286 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | Camilla Sylvest |
| **2** | **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff |
| **2** | **Reason for the notification** | **Reason for the notification** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Position/status | Executive Vice President | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** | **Details of the issuer** |
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) | Other transaction (transfer of shares in<br> accordance with Long Term Incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 26,984 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 26,984 Shares<br> DKK 0.00 | <br> 26,984 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**1** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** | &nbsp;&nbsp;**Details of the person discharging managerial responsibilities/person closely associated** |
| a) | Name of the Board member/Executive/Associated Person | Henrik Ehlers Wulff |
| **2** | **Reason for the notification** | **Reason for the notification** |
| a) | Position/status | Executive Vice President |
| b) | Initial notification/Amendment | Initial notification |
| **3** | **Details of the issuer** | **Details of the issuer** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

---

| | | | |
|:---|:---|:---|:---|
| a) | Name | Novo Nordisk A/S | Novo Nordisk A/S |
| b) | LEI | 549300DAQ1CVT6CXN342 | 549300DAQ1CVT6CXN342 |
| **4** | **Details of the transaction(s)** | **Details of the transaction(s)** | **Details of the transaction(s)** |
| a) | Description of the financial instrument,<br> type of instrument, | Shares |  |
| a) | Identification code | Novo Nordisk B DK0060534915 | Novo Nordisk B DK0060534915 |
| b) | Nature of the transaction | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) | Other transaction (transfer of shares in<br> accordance with restricted stock unit incentive programme) |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| c) | Price(s) and volume(s) | DKK 0.00 | 75 shares |
| c) | Price(s) and volume(s) |  |  |
| c) | Price(s) and volume(s) |  |  |
| d) | Aggregated information<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Aggregated volume<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Price | <br> 75 Shares<br> DKK 0.00 | <br> 75 Shares<br> DKK 0.00 |
| e) | Date of the transaction | 2023-02-01 | 2023-02-01 |
| f) | Place of the transaction | Outside a trading venue | Outside a trading venue |

---

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.*

 

 

 

 

 

 

 

 

 

 

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

**Contact for further information**

---

| | |
|:---|:---|
| **Media:** |  |
| **Ambre Brown Morley**<br> +45 3079 9289<br> abmo@novonordisk.com | **Natalia Salomao Abrahao (US)**<br> +1 848 304 1027<br> niaa@novonordisk.com |
| **Investors:** |  |
| **Daniel Muusmann Bohsen**<br> +45 3075 2175<br> dabo@novonordisk.com | **Jacob Martin Wiborg Rode**<br> +45 3075 5956<br> jrde@novonordisk.com |
| **David Heiberg Landsted**<br> +45 3077 6915<br> dhel@novonordisk.com | **Mark Joseph Root (US)**<br> +1 848 213 3219<br> mjhr@novonordisk.com |

---

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br> Investor Relations | Novo Allé<br> 2880 Bagsværd<br> Denmark | Telephone:<br> +45 4444 8888 | <br> www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  | Company announcement No 6 / 2023 | Company announcement No 6 / 2023 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 2, 2023 NOVO NORDISK A/S <u>Lars Fruergaard Jørgensen</u> Chief Executive Officer